Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

VICTORIA

Projekt: Typer af projekter

  1. ORION-8

    Projekt: Typer af projekter

  2. Determine 01 (HFpEF)

    Projekt: Typer af projekter

  3. Determine 02 (HFrEF)

    Projekt: Typer af projekter

  4. Dan-Heart

    Projekt: Typer af projekter

  5. Select

    Projekt: Typer af projekter

  6. DANBLOCK

    Projekt: Typer af projekter

  7. AEGIS-2

    Projekt: Typer af projekter

  8. ODYSSEY LEGACY

    Projekt: Typer af projekter

  9. EFC14875/Scored

    Projekt: Typer af projekter

  10. LTOLE/COMPASS

    Projekt: Typer af projekter

Vis graf over relationer
A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi-Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) - VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA)
This is a randomized, placebo-controlled, parallel-group, multi-center, double-blind, event driven study of vericiguat (MK-1242) in participants with HFrEF. The primary hypothesis is vericiguat (MK-1242) is superior to placebo in increasing the time to first occurrence of the composite of cardiovascular (CV) death or heart failure (HF) hospitalization in participants with HFrEF
StatusIgangværende
Periode01/12/201601/01/2020
URLNCT02861534

ID: 49755167